{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:07:10Z","timestamp":1790701630062,"version":"4.1.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,5]],"date-time":"2019-11-05T00:00:00Z","timestamp":1572912000000},"content-version":"vor","delay-in-days":1099,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1093\/annonc\/mdw317","type":"journal-article","created":{"date-parts":[[2016,8,30]],"date-time":"2016-08-30T00:33:16Z","timestamp":1472517196000},"page":"2032-2038","source":"Crossref","is-referenced-by-count":83,"title":["Treatment with methylnaltrexone is associated with increased survival in patients with advanced cancer"],"prefix":"10.1016","volume":"27","author":[{"given":"F.","family":"Janku","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.K.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.D.","family":"Karp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.T.","family":"Atkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.A.","family":"Singleton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Moss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdw317_bb0010","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1002\/cncr.29460","article-title":"The mu opioid receptor: a new target for cancer therapy?","volume":"121","author":"Singleton","year":"2015","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdw317_bb0015","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.4065\/83.10.1116","article-title":"Development of peripheral opioid antagonists\u2019 new insights into opioid effects","volume":"83","author":"Moss","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"10.1093\/annonc\/mdw317_bb0020","first-page":"4491","article-title":"Morphine stimulates angiogenesis by activating proangiogenic and survival-promoting signaling and promotes breast tumor growth","volume":"62","author":"Gupta","year":"2002","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdw317_bb0025","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1158\/1535-7163.MCT-07-2217","article-title":"Synergistic effects of methylnaltrexone with 5-fluorouracil and bevacizumab on inhibition of vascular endothelial growth factor-induced angiogenesis","volume":"7","author":"Singleton","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"10.1093\/annonc\/mdw317_bb0030","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.mvr.2006.04.004","article-title":"Methylnaltrexone inhibits opiate and VEGF-induced angiogenesis: role of receptor transactivation","volume":"72","author":"Singleton","year":"2006","journal-title":"Microvasc Res"},{"key":"10.1093\/annonc\/mdw317_bb0035","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/2040-2384-2-5","article-title":"Methylnaltrexone potentiates the anti-angiogenic effects of mTOR inhibitors","volume":"2","author":"Singleton","year":"2010","journal-title":"J Angiogenes Res"},{"issue":"Suppl. 1","key":"10.1093\/annonc\/mdw317_bb0040","doi-asserted-by":"crossref","first-page":"i103","DOI":"10.1093\/bja\/aeu165","article-title":"Increased mu-opioid receptor expression in metastatic lung cancer","volume":"113","author":"Singleton","year":"2014","journal-title":"Br J Anaesth"},{"key":"10.1093\/annonc\/mdw317_bb0045","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1165\/rcmb.2006-0327OC","article-title":"Attenuation of vascular permeability by methylnaltrexone: role of mOP-R and S1P3 transactivation","volume":"37","author":"Singleton","year":"2007","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1093\/annonc\/mdw317_bb0050","first-page":"59","article-title":"Opioid-induced proliferation of vascular endothelial cells","volume":"2","author":"Leo","year":"2009","journal-title":"J Pain Res"},{"key":"10.1093\/annonc\/mdw317_bb0055","doi-asserted-by":"crossref","first-page":"e91577","DOI":"10.1371\/journal.pone.0091577","article-title":"The mu opioid receptor promotes opioid and growth factor-induced proliferation, migration and epithelial mesenchymal transition (EMT) in human lung cancer","volume":"9","author":"Lennon","year":"2014","journal-title":"PLoS One"},{"key":"10.1093\/annonc\/mdw317_bb0060","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1213\/ANE.0b013e31820568af","article-title":"The novel role of the mu opioid receptor in lung cancer progression: a laboratory investigation","volume":"112","author":"Mathew","year":"2011","journal-title":"Anesth Analg"},{"key":"10.1093\/annonc\/mdw317_bb0065","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/00008390-200004000-00009","article-title":"Prognostic impact of the type of anaesthesia used during the excision of primary cutaneous melanoma","volume":"10","author":"Schlagenhauff","year":"2000","journal-title":"Melanoma Res"},{"key":"10.1093\/annonc\/mdw317_bb0070","doi-asserted-by":"crossref","first-page":"4103","DOI":"10.1002\/cncr.28345","article-title":"Opioid requirement, opioid receptor expression, and clinical outcomes in patients with advanced prostate cancer","volume":"119","author":"Zylla","year":"2013","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdw317_bb0075","doi-asserted-by":"crossref","DOI":"10.1093\/bja\/aeu351","article-title":"Association of opioid requirement and cancer pain with survival in advanced non-small cell lung cancer","author":"Zylla","year":"2014","journal-title":"Br J Anaesth"},{"key":"10.1093\/annonc\/mdw317_bb0080","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/SPC.0000000000000056","article-title":"Opioids and cancer recurrence","volume":"8","author":"Juneja","year":"2014","journal-title":"Curr Opin Support Palliat Care"},{"key":"10.1093\/annonc\/mdw317_bb0085","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/hed.21759","article-title":"Modulation of the opioid growth factor ([Met(5)]-enkephalin)-opioid growth factor receptor axis: novel therapies for squamous cell carcinoma of the head and neck","volume":"34","author":"McLaughlin","year":"2012","journal-title":"Head Neck"},{"issue":"Suppl 1","key":"10.1093\/annonc\/mdw317_bb0090","doi-asserted-by":"crossref","first-page":"i4","DOI":"10.1093\/bja\/aeu090","article-title":"Morphine stimulates cancer progression and mast cell activation and impairs survival in transgenic mice with breast cancer","volume":"113","author":"Nguyen","year":"2014","journal-title":"Br J Anaesth"},{"key":"10.1093\/annonc\/mdw317_bb0095","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1600-0625.2010.01158.x","article-title":"Endogenous mu-opioid peptides modulate immune response towards malignant melanoma","volume":"20","author":"Boehncke","year":"2011","journal-title":"Exp Dermatol"},{"key":"10.1093\/annonc\/mdw317_bb0100","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1097\/ALN.0b013e31824b96a1","article-title":"mu-Opioid receptor gene A118G polymorphism predicts survival in patients with breast cancer","volume":"116","author":"Bortsov","year":"2012","journal-title":"Anesthesiology"},{"key":"10.1093\/annonc\/mdw317_bb0105","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1097\/j.pain.0000000000000136","article-title":"Morphine does not facilitate breast cancer progression in two preclinical mouse models for human invasive lobular and HER2(+) breast cancer","volume":"156","author":"Doornebal","year":"2015","journal-title":"Pain"},{"key":"10.1093\/annonc\/mdw317_bb0110","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1002\/cam4.236","article-title":"A retrospective analysis of the effect of intraoperative opioid dose on cancer recurrence after non-small cell lung cancer resection","volume":"3","author":"Cata","year":"2014","journal-title":"Cancer Med"},{"issue":"Suppl. 1","key":"10.1093\/annonc\/mdw317_bb0115","doi-asserted-by":"crossref","first-page":"i88","DOI":"10.1093\/bja\/aeu192","article-title":"Association of increased postoperative opioid administration with non-small-cell lung cancer recurrence: a retrospective analysis","volume":"113","author":"Maher","year":"2014","journal-title":"Br J Anaesth"},{"key":"10.1093\/annonc\/mdw317_bb0120","first-page":"39","article-title":"Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients","volume":"7","author":"Slatkin","year":"2009","journal-title":"J Support Oncol"},{"key":"10.1093\/annonc\/mdw317_bb0125","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1089\/jpm.2014.0362","article-title":"Fixed-dose subcutaneous methylnaltrexone in patients with advanced illness and opioid-induced constipation: results of a randomized, placebo-controlled study and open-label extension","volume":"18","author":"Bull","year":"2015","journal-title":"J Palliat Med"},{"key":"10.1093\/annonc\/mdw317_bb0130","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1056\/NEJMoa0707377","article-title":"Methylnaltrexone for opioid-induced constipation in advanced illness","volume":"358","author":"Thomas","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdw317_bb0135","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimator from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.1093\/annonc\/mdw317_bb0140","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life tables (with discussion)","volume":"34","author":"Cox","year":"1972","journal-title":"J R Stat Soc B"},{"key":"10.1093\/annonc\/mdw317_bb0145","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1093\/annonc\/mdw317_bb0150","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1200\/JCO.2008.19.5081","article-title":"Prospective validation of a prognostic score to improve patient selection for oncology phase I trials","volume":"27","author":"Arkenau","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw317_bb0155","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1038\/sj.bjc.6604218","article-title":"Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience","volume":"98","author":"Arkenau","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdw317_bb0160","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1097\/ALN.0b013e31824babe2","article-title":"Overexpression of the mu-opioid receptor in human non-small cell lung cancer promotes Akt and mTOR activation, tumor growth, and metastasis","volume":"116","author":"Lennon","year":"2012","journal-title":"Anesthesiology"},{"key":"10.1093\/annonc\/mdw317_bb0165","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1097\/ALN.0b013e31824b9512","article-title":"The mu-opioid receptor in cancer progression: is there a direct effect?","volume":"116","author":"Lennon","year":"2012","journal-title":"Anesthesiology"},{"key":"10.1093\/annonc\/mdw317_bb0170","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1002\/cncr.29532","article-title":"Opioids and breast cancer recurrence: a Danish population-based cohort study","volume":"121","author":"Cronin-Fenton","year":"2015","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdw317_bb0175","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1097\/00000542-200610000-00008","article-title":"Can anesthetic technique for primary breast cancer surgery affect recurrence or metastasis?","volume":"105","author":"Exadaktylos","year":"2006","journal-title":"Anesthesiology"},{"key":"10.1093\/annonc\/mdw317_bb0180","doi-asserted-by":"crossref","first-page":"e56540","DOI":"10.1371\/journal.pone.0056540","article-title":"The effect of anesthetic technique on survival in human cancers: a meta-analysis of retrospective and prospective studies","volume":"8","author":"Chen","year":"2013","journal-title":"PLoS One"},{"key":"10.1093\/annonc\/mdw317_bb0185","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.jpain.2015.05.006","article-title":"A systematic review of prospective studies reporting adverse events of commonly used opioids for cancer-related pain: a call for the use of standardized outcome measures","volume":"16","author":"Oosten","year":"2015","journal-title":"J Pain"},{"key":"10.1093\/annonc\/mdw317_bb0190","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1002\/1097-0142(19870215)59:4<850::AID-CNCR2820590432>3.0.CO;2-1","article-title":"A validation study of the WHO method for cancer pain relief","volume":"59","author":"Ventafridda","year":"1987","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdw317_bb0195","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1007\/DCR.0b013e3182092bde","article-title":"Safety and efficacy of methylnaltrexone in shortening the duration of postoperative ileus following segmental colectomy: results of two randomized, placebo-controlled phase 3 trials","volume":"54","author":"Yu","year":"2011","journal-title":"Dis Colon Rectum"},{"key":"10.1093\/annonc\/mdw317_bb0200","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jclinane.2015.02.007","article-title":"Cancer surgery: how may anesthesia influence outcome?","volume":"27","author":"Cassinello","year":"2015","journal-title":"J Clin Anesth"},{"key":"10.1093\/annonc\/mdw317_bb0205","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2217\/pmt.15.21","article-title":"Best practice in the administration of analgesia in postoncological surgery","volume":"5","author":"Cata","year":"2015","journal-title":"Pain Manage"},{"key":"10.1093\/annonc\/mdw317_bb0210","doi-asserted-by":"crossref","first-page":"695","DOI":"10.6004\/jnccn.2016.0195","article-title":"Cancer pain management: strategies for safe and effective opioid prescribing","volume":"14","author":"Paice","year":"2016","journal-title":"J Natl Compr Canc Netw"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419358351?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419358351?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/27\/11\/2032\/19446556\/mdw317.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T03:27:31Z","timestamp":1718767651000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419358351"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":41,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["S0923753419358351"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdw317","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]}}}